Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Aug 25, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.173, Tislelizumab-jsgr (Tevimbra®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Aug 25, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.173 has been established for Tislelizumab-jsgr (Tevimbra®), a pharmacy/drug coverage policy. This appears to be setting coverage guidelines for this specific medication under Medicare Advantage plans.

Action Required

Action needed

Before August 25, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing guidelines for Tislelizumab-jsgr (Tevimbra®). Update pharmacy benefit management protocols and inform providers who may prescribe this medication.

Related policy hubs

Independence Blue Cross policies Oncology Hematology